A question for you

Did Biota's announcement yesterday mean that they have been granted an extension of patent (and therefore royalties) over relenza, or not? Read it




As previously reported on August 25, 2014, GlaxoSmithKline, plc (GSK) filed an appeal to the United States Patent Trial and Appeal Board in relation to the pending patent application No. 08/737,141 related to Relenza ^® . On March 16, 2015, the company was informed that the United States Patent Trial and Appeal Board had issued a decision denying the appeal and affirming the Examiner’s prima facie case of obviousness rejection under 35 U.S.C. 103(a). GSK and the company intend to pursue available legal options with respect to this decision and to continue to seek issuance of this pending patent. No assurance can be given that the pursuit of any such options will be successful. Issued patents relating to Relenza ^® outside of the Unite States are unaffected, and will expire in May 2015 in the major countries of the European Union, and July 2019 in Japan.



Trying to find a plain English translation somewhere.

It appears GSKs appeal against patent extension was denied. Why are both GSK and BOTA pursuing legal options?

press releases index

it's heartening to see news coming.

Commencing vap trial and presenting at conferences is all positive.

We really need to see the press release announcing the rest of world deal for LANI. Based on the anaconda deal numbers it should be worth much more than I have previously proposed. And I hope the anaconda deal was done with the understanding that the LANI deal would soon increase cash reserves.

So with RSV compound at Phase 1, Vapendavir in Phase 2 b, Anaconda's drug coming to Phase 2b, and LANI potentially at Phase 3: well, that's reasonable biotech-bait.